Gustav Gaudernack

ORCID: 0000-0002-9678-7447
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • T-cell and B-cell Immunology
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Research and Treatments
  • vaccines and immunoinformatics approaches
  • Virus-based gene therapy research
  • RNA Interference and Gene Delivery
  • Genetic factors in colorectal cancer
  • Immune Response and Inflammation
  • Cancer Genomics and Diagnostics
  • Glycosylation and Glycoproteins Research
  • Hematopoietic Stem Cell Transplantation
  • Colorectal Cancer Treatments and Studies
  • Cancer Cells and Metastasis
  • Cell Adhesion Molecules Research
  • Platelet Disorders and Treatments
  • Lymphoma Diagnosis and Treatment
  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Screening and Detection
  • Prostate Cancer Treatment and Research
  • Microfluidic and Capillary Electrophoresis Applications
  • Diabetes and associated disorders

University of Oslo
2009-2023

Oslo University Hospital
2013-2023

Ultimovacs (Norway)
2016-2023

Norwegian Cancer Society
2001-2014

Faculty (United Kingdom)
2012-2013

Med-Storm Innovation (Norway)
2007

Norsk Hydro (Norway)
1992-2001

UiT The Arctic University of Norway
1977-1997

Diakonhjemmet Hospital
1997

Institute of Immunology
1992-1996

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients colorectal cancer were invited to provide that data in a schematized format for inclusion collaborative database called RASCAL (The in-colorectal-cancer group). Our results from 2721 such have been presented previously first time any common cancer, showed conclusively different gene mutations impacts on outcome, even when occur at same site genome. To explore effect Ki-ras stages...

10.1054/bjoc.2001.1964 article EN cc-by-nc-sa British Journal of Cancer 2001-08-01

The growth and recurrence of several cancers appear to be driven by a population cancer stem cells (CSCs). Glioblastoma, the most common primary brain tumor, is invariably fatal, with median survival approximately 1 year. Although experimental data have suggested importance CSCs, few exist regarding potential relevance these in clinical setting.We here present first seven patients treated dendritic cell (DC)-based vaccine targeting CSCs solid tumor. Brain tumor biopsies were dissociated into...

10.1007/s00262-013-1453-3 article EN cc-by Cancer Immunology Immunotherapy 2013-07-01

Patients with inoperable pancreatic cancer have a dismal prognosis mean life expectancy of 3–6 months. New treatment modalities are thus urgently needed. Telomerase is expressed in 85–90% pancreas cancer, and immunogenic telomerase peptides been characterised. A phase I/II study was conducted to investigate the safety, tolerability, immunogenecity peptide vaccination. Survival patients also recorded. Forty-eight non-resectable received intradermal injections GV1001 at three dose levels,...

10.1038/sj.bjc.6603437 article EN cc-by-nc-sa British Journal of Cancer 2006-10-24

This paper describes a new cell isolation and HLA typing technique, which permits separation class I or II to be performed in 70 min. Magnetic monodisperse microspheres (Dynabeads TM) were coated with monoclonal antibodies (MAbs) specific for the CD8 T antigen monomorphic epitopes. They could then used obtain positive cells directly from ACD blood approximately 15 min by use of magnetic separation. The (attached microspheres) subsequently microcytotoxic (total incubation time 55 min) using...

10.1111/j.1399-0039.1986.tb00500.x article EN Tissue Antigens 1986-11-01

K-RAS mutations are frequently found in adenocarcinomas of the pancreas, and induction immunity against mutant ras can therefore be possible clinical benefit patients with pancreatic cancer. We present data from a phase I/II trial involving adenocarcinoma pancreas vaccinated by i.d. injection synthetic peptides combination granulocyte-macrophage colony-stimulating factor. Forty-eight (10 surgically resected 38 advanced disease) were treated on an outpatient basis. Peptide-specific was...

10.1002/ijc.1205 article EN International Journal of Cancer 2001-01-01

The functional role and specificity of tumor infiltrating lymphocytes (TIL) is generally not well characterized. Prominent lymphocyte infiltration the hallmark most common form hereditary colon cancer, nonpolyposis cancer (HNPCC) corresponding spontaneous cancers with microsatellite instability (MSI) phenotype. These are caused by inherited or acquired defects in DNA mismatch–repair machinery. molecular mechanism behind MSI phenotype provides a clue to understanding reaction allowing...

10.1073/pnas.231326898 article EN Proceedings of the National Academy of Sciences 2001-10-30

We demonstrated that the in vitro differentiation of human peripheral blood monocytes to macrophages is dependent on environment and conditions monocyte culture. Cultivation glass or microexudate-coated gave rise cells resembling foreign body granuloma macrophages. After an initial Fc receptor- C3 receptor-mediated phagocytosis, a progressive loss receptor expression C3-mediated ingestion were observed. The surface antigens recognized by anti-human monoclonal antibodies 1D5 63D3 lost from...

10.1084/jem.156.4.1101 article EN The Journal of Experimental Medicine 1982-10-01

Abstract K‐ras mutations are frequently found in adenocarcinomas of the pancreas and can elicit mutation‐specific immune responses. Targeting system against mutant Ras may thus influence clinical course disease. Twenty‐three patients who were vaccinated after surgical resection for pancreatic adenocarcinoma (22 pancreaticoduodenectomies, one distal resection), two previous Phase I/II trials, followed more than 10 years with respect to long‐term immunological T‐cell reactivity survival. The...

10.1002/ijc.25449 article EN International Journal of Cancer 2010-05-12

Abstract Purpose: We report two clinical trials in non–small cell lung cancer (NSCLC) patients evaluating immune response, toxicity, and outcome after vaccination with the telomerase peptide GV1001: a phase II trial (CTN-2006) vaccinated chemoradiotherapy an 8-year update on previously reported I/II (CTN-2000). Experimental Design: CTN-2006: 23 inoperable stage III received radiotherapy (2 Gy × 30) weekly docetaxel (20 mg/m2), followed by GV1001 vaccination. CTN-2000: 26 were peptides...

10.1158/1078-0432.ccr-11-1385 article EN Clinical Cancer Research 2011-09-15

Cancer cells escape T-cell-mediated destruction by losing human leukocyte antigen (HLA) class I expression via various mechanisms, including loss of beta2-microglobulin (β2m). Our study illustrates the immune HLA I-negative tumor and chronological sequence appearance β2m gene mutation in successive lesions obtained from a patient with metastatic melanoma. We observed gradual decrease consecutive few HLA-negative nodules primary emergence totally negative lesion at later stages disease....

10.1002/ijc.28338 article EN International Journal of Cancer 2013-06-20

Lung cancer (LC) with its different subtypes is generally known as a therapy resistant the highest morbidity rate worldwide. Therapy resistance of tumor thought to be related stem cells (CSCs) within tumors. There have been indications that lung propagated and maintained by small population CSCs. To study this question we established panel 15 primary cell lines (PLCCLs) from 20 fresh tumors using robust serum-free culture system. We subsequently focused on identification CSCs studying these...

10.1371/journal.pone.0057020 article EN cc-by PLoS ONE 2013-03-04

During the current COVID-19 pandemic, a need for evaluation of already available drugs treatment disease is crucial. Hereby, based on literature review from pandemic and previous outbreaks with corona viruses we analyze impact virus infection cell stress responses redox balance. High levels mortality are noticed in elderly individuals infected SARS-CoV2 during SARS-CoV1 outbreak. Elderly maintain chronic low level inflammation which associated oxidative inflammatory cytokine production,...

10.1016/j.toxrep.2020.06.003 article EN cc-by Toxicology Reports 2020-01-01

Mutations in the k-ras and TP53 genes, as well microsatellite instability (MIN), are frequent genetic alterations colorectal carcinomas represent 3 different mechanisms carcinogenic process. Both incidence of cancer frequency such tumours have been related to clinico-pathological variables, including age gender patient location tumour. A number studies also reported associations between types alterations. We therefore wanted explore relationship these variables using multivariate analysis on...

10.1002/(sici)1097-0215(19971219)74:6<664::aid-ijc18>3.0.co;2-5 article EN International Journal of Cancer 1997-12-19

Mutant p21-ras proteins contain sequences that distinguish them from normal ras, and represent unique epitopes for T-cell recognition of antigen-bearing tumour cells. Here, we examined the capacity CD4+ CD8+ T cells, generated simultaneously by mutant-ras-peptide vaccination a pancreatic-adenocarcinoma patient, to recognize lyse autologous cells harbouring corresponding activated K-ras epitopes. The patient was vaccinated with purified 17mer ras peptide (KLVVVGAVGVGKSALTI), containing Gly12...

10.1002/(sici)1097-0215(19970904)72:5<784::aid-ijc14>3.0.co;2-9 article EN International Journal of Cancer 1997-09-04

Peripheral node addressin (PNAd) is a complex mixture of glycoproteins with L-selectin ligand activity that functions in lymphocyte homing. We have investigated the contribution sialomucin CD34 relative to other components PNAd tethering and rolling vitro laminar flow assays. was isolated MECA-79 mAb-Sepharose from tonsillar stroma, component (PNAd,CD34+) CD34-negative (PNAd,CD34-) separated on mAb-Sepharose. Lymphocytes PNAd,CD34- fraction tether less efficiently, roll faster are resistant...

10.1083/jcb.131.1.261 article EN The Journal of Cell Biology 1995-10-01
Coming Soon ...